NASDAQ:GNMX Aevi Genomic Medicine (GNMX) Stock Price, News & Analysis → The last Republican president? (From The Freeport Society) (Ad) Free GNMX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.15▼$0.1850-Day Range$0.17▼$0.1952-Week Range$0.11▼$0.35Volume2.95 million shsAverage Volume3.16 million shsMarket Capitalization$12.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aevi Genomic Medicine alerts: Email Address Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Aevi Genomic Medicine Stock (NASDAQ:GNMX)Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.Read More Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. GNMX Stock News HeadlinesFebruary 9, 2024 | benzinga.comPlc Astrazeneca's Net WorthSeptember 10, 2023 | thestreet.comAevi Genomic Medicine, Inc.March 11, 2023 | marketwatch.comForecast 2023-2027, Genomic Medicine Market: An Analysing Business Strategies and TrendsMarch 7, 2023 | finance.yahoo.comSucheta Bhatt, MD, FACMG and Rong Mao, MD, FACMG Elected to Board of Directors of the ACMG Foundation for Genetic and Genomic MedicineFebruary 24, 2023 | marketwatch.comThe Rise of Genomic Medicine Market Research 2023-2027: Opportunities and Challenges with Top Countries DataJanuary 30, 2023 | finance.yahoo.comNutritional Genomics Company, GenoPalate, Launches Personalized Supplement Line, GenoVitJanuary 26, 2023 | finanznachrichten.deGenomic Vision Strengthens Leadership Team With the Appointment of Frederic Hammel as Chief Operating OfficerOctober 7, 2022 | finance.yahoo.comDante Genomics Unveils Digital Health Population Genomic Programs at the United Nations General Assembly Science SummitSee More Headlines Receive GNMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aevi Genomic Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2018Today6/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GNMX Previous SymbolNASDAQ:MDGN CUSIPN/A CIK1138776 Webwww.aevigenomics.com Phone610-254-4201FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-898.31% Return on Assets-286.73% Debt Debt-to-Equity RatioN/A Current Ratio0.65 Quick Ratio0.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book1.38Miscellaneous Outstanding Shares77,714,000Free FloatN/AMarket Cap$12.89 million OptionableOptionable Beta1.13 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Michael F. Cola (Age 59)CEO, Pres & Director Mr. Brian D. Piper (Age 47)CFO & Corp. Sec. Dr. Garry A. Neil (Age 65)Chief Scientific Officer Key CompetitorsAligos TherapeuticsNASDAQ:ALGSOKYO PharmaNASDAQ:OKYOAchilles TherapeuticsNASDAQ:ACHLNKGen BiotechNYSE:NKGNCyclo TherapeuticsNASDAQ:CYTHView All Competitors GNMX Stock Analysis - Frequently Asked Questions How were Aevi Genomic Medicine's earnings last quarter? Aevi Genomic Medicine, LLC (NASDAQ:GNMX) released its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.03. What other stocks do shareholders of Aevi Genomic Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aevi Genomic Medicine investors own include Novavax (NVAX), Co-Diagnostics (CODX), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), iBio (IBIO), Immunomedics (IMMU), Actinium Pharmaceuticals (ATNM), Biocept (BIOC) and MEI Pharma (MEIP). This page (NASDAQ:GNMX) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aevi Genomic Medicine, LLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Aevi Genomic Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.